The role of different genetic subtypes of CEBPA mutated AML. (Q43746366)

26 November 2017

The role of different genetic subtypes of CEBPA mutated AML. (English)

1 reference

26 November 2017

12

T Haferlach

1 reference

26 November 2017

2

C Haferlach

1 reference

26 November 2017

13

S Schnittger

1 reference

26 November 2017

A Fasan

1

1 reference

26 November 2017

T Alpermann

3

1 reference

26 November 2017

S Jeromin

4

1 reference

26 November 2017

V Grossmann

5

1 reference

26 November 2017

C Eder

6

1 reference

26 November 2017

S Weissmann

7

1 reference

26 November 2017

F Dicker

8

1 reference

26 November 2017

A Kohlmann

9

1 reference

26 November 2017

S Schindela

10

1 reference

26 November 2017

W Kern

11

1 reference

26 November 2017

23 September 2013

1 reference

26 November 2017

1 reference

26 November 2017

28

1 reference

26 November 2017

4

1 reference

26 November 2017

794-803

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2013.273

26 November 2017

0 references

cites work

Dysregulation of the C/EBPalpha differentiation pathway in human cancer

1 reference

12 December 2020

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients

1 reference

12 December 2020

Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.

1 reference

12 December 2020

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study

1 reference

12 December 2020

Segmental uniparental disomy as a recurrent mechanism for homozygous CEBPA mutations in acute myeloid leukemia

1 reference

12 December 2020

Implications of NRAS mutations in AML: a study of 2502 patients

1 reference

12 December 2020

Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia

1 reference

12 December 2020

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity

1 reference

12 December 2020

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)

1 reference

12 December 2020

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

1 reference

12 December 2020

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study

1 reference

12 December 2020

GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis

1 reference

12 December 2020

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

1 reference

12 December 2020

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

1 reference

12 December 2020

CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis

1 reference

12 December 2020

Landscape of TET2 mutations in acute myeloid leukemia

1 reference

12 December 2020

Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML

1 reference

12 December 2020

Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis

1 reference

12 December 2020

Transcription factors, normal myeloid development, and leukemia

1 reference

12 December 2020

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

1 reference

12 December 2020

Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2.

1 reference

12 December 2020

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome

1 reference

12 December 2020

Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia

1 reference

12 December 2020

C/EBPalpha mutations in acute myeloid leukaemias

1 reference

12 December 2020

Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.

1 reference

12 December 2020

Robustness of Amplicon Deep Sequencing Underlines Its Utility in Clinical Applications

1 reference

12 December 2020

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

1 reference

12 December 2020

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status

1 reference

12 December 2020

CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations

1 reference

12 December 2020

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

12 December 2020

Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients

1 reference

12 December 2020

Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology

1 reference

12 December 2020

Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia

1 reference

12 December 2020

Morphologic dysplasia in acute myeloid leukemia: importance of granulocytic dysplasia

1 reference

12 December 2020

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

1 reference

12 December 2020

Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.

1 reference

12 December 2020

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia

1 reference

12 December 2020

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2013.273

1 reference

Dimensions Publication ID

26 November 2017

0 references

1 reference